Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference

Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) announced that CEO Paul R. Edick will present at the H.C. Wainwright BioConnect 2021 virtual conference from January 11-14, 2021. The presentation will provide an overview of the company's innovative drug technologies, including its proprietary XeriSol™ and XeriJect™ platforms that offer stable, ready-to-use formulations. A webcast will be available starting January 11 at 6:00 a.m. E.T. on the company's website.

Xeris aims to simplify administration of vital therapies, benefiting patients and healthcare systems.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the H.C. Wainwright BioConnect 2021 virtual conference being held January 11-14, 2021.

A webcast of the on-demand presentation will be available beginning January 11, 2021 at 6:00 a.m. E.T. through the investors section on the Company's website at www.xerispharma.com.

About Xeris Pharmaceuticals, Inc.

Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005826/en/

FAQ

What will Paul R. Edick present at the H.C. Wainwright BioConnect 2021 conference?

Paul R. Edick will present an overview of Xeris Pharmaceuticals and its innovative drug technologies.

When is the H.C. Wainwright BioConnect 2021 conference?

The conference is being held from January 11-14, 2021.

Where can I watch the Xeris Pharmaceuticals presentation?

The presentation will be available as a webcast on Xeris' website starting January 11, 2021, at 6:00 a.m. E.T.

What are Xeris Pharmaceuticals' key technologies?

Xeris utilizes XeriSol™ and XeriJect™ technologies to provide ready-to-use, room-temperature stable formulations.

What is the significance of Xeris' drug formulations?

Their formulations simplify therapy administration, reduce costs, and eliminate the need for reconstitution or IV infusion.